{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:06Z","timestamp":1787008626901,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI104681)"],"award-info":[{"award-number":["UM1AI104681)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018131","name":"Durham Center of Innovation to Accelerate Discovery and Practice Transformation","doi-asserted-by":"publisher","award":["CIN 13-410"],"award-info":[{"award-number":["CIN 13-410"]}],"id":[{"id":"10.13039\/100018131","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Durham Veterans Affairs Health Care System"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This manuscript presents key advances of the Antibacterial Resistance Leadership Group (ARLG) Innovations Task Force, a collaboration focused on improving endpoints for registrational trials of antibacterial drugs, including health-related quality-of-life measures, for common acute infections. This group includes members from the United States Food and Drug Administration, National Institutes of Health, academia, industry, and patient representatives to amplify patient voices and ensure that the endpoints are meaningful to how patients feel, function, and survive.<\/jats:p>","DOI":"10.1093\/cid\/ciaf298","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:46:33Z","timestamp":1749023193000},"page":"S11-S15","source":"Crossref","is-referenced-by-count":1,"title":["Interagency Collaboration for Patient-Centered Antibacterial Drug Development"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-0458","authenticated-orcid":false,"given":"Jessica","family":"Howard-Anderson","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-6014","authenticated-orcid":false,"given":"Sarah B","family":"Doernberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Dixon","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Gopinath","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rubin","sequence":"additional","affiliation":[{"name":"Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tori","family":"Kinamon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-0964","authenticated-orcid":false,"given":"Deborah","family":"Collyar","sequence":"additional","affiliation":[{"name":"Patient Advocates in Research (PAIR) , Danville, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-4331","authenticated-orcid":false,"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-0897","authenticated-orcid":false,"given":"Vance G","family":"Fowler","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-4491","authenticated-orcid":false,"given":"Henry F","family":"Chambers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-172X","authenticated-orcid":false,"given":"Scott R","family":"Evans","sequence":"additional","affiliation":[{"name":"Biostatistics Center and Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, The George Washington University , Washington, D.C. ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-9010","authenticated-orcid":false,"given":"Thomas L","family":"Holland","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A","family":"King","sequence":"additional","affiliation":[{"name":"Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System , Durham, North Carolina ,","place":["USA"]},{"name":"Department of Population Health Sciences, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W","family":"Boucher","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine and Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025081213290902100_ciaf298-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2025081213290902100_ciaf298-B2","volume-title":"Antibacterial agents in clinical and preclinical development: an overview and analysis","author":"World Health Organization (WHO)","year":"2021"},{"key":"2025081213290902100_ciaf298-B3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciab141","article-title":"Antibacterial Resistance Leadership Group 2.0: back to business","volume":"73","author":"Chambers","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B4","volume-title":"National action plan for combating antibiotic-resistant bacteria 2020\u20132025.","author":"Federal Task Force on Combating Antibiotic-Resistant Bacteria"},{"key":"2025081213290902100_ciaf298-B5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciaa611","article-title":"Patients\u2019 experiences with Staphylococcus aureus and gram-negative bacterial bloodstream infections: a qualitative descriptive study and concept elicitation phase to inform measurement of patient-reported quality of life","volume":"73","author":"King","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciaa616","article-title":"Measuring the meaningful","volume":"73","author":"McNamara","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"2025081213290902100_ciaf298-B8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"issue":"Suppl 1","key":"2025081213290902100_ciaf298-B9","doi-asserted-by":"crossref","first-page":"ofae631.1726","DOI":"10.1093\/ofid\/ofae631.1726","article-title":"P-1559. Comparing patient and clinician perceptions of health-related quality of life in hospitalized patients with complicated urinary tract infections: a qualitative descriptive study","volume":"12","author":"Howard-Anderson","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025081213290902100_ciaf298-B10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"2025081213290902100_ciaf298-B12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B13","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial End points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciad239","article-title":"Exploration of a potential DOOR endpoint for complicated intra-abdominal infections using nine registrational trials for antibacterial drugs","volume":"77","author":"Kinamon","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025081213290902100_ciaf298-B15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/cid\/ciad576","article-title":"Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"78","author":"Howard-Anderson","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2025081213290902100_ciaf298-B16","first-page":"ofae631.02","article-title":"Improving traditional registrational trial endpoints: development and application of a desirability of outcome ranking (DOOR) endpoint for acute bacterial skin and skin-structure infections","volume":"12","author":"Howard-Anderson","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025081213290902100_ciaf298-B17","author":"Antibacterial Resistance Leadership Group","year":"2022"},{"key":"2025081213290902100_ciaf298-B18","author":"The George Washington University Biostatistics Center"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_1\/S11\/63962303\/ciaf298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_1\/S11\/63962303\/ciaf298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:29:16Z","timestamp":1755019756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/Supplement_1\/S11\/8222866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":18,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf298","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,8,6]]}}}